End Points and Clinical Trial Design in Pulmonary Arterial Hypertension
Vallerie V. McLaughlin(University of Michigan), Werner Seeger(Justus-Liebig-Universität Gießen), J. Simon R. Gibbs(National Institutes of Health), Steeve Provencher(Institut universitaire de cardiologie et de pneumologie de Québec), Ronald J. Oudiz(University of California, Los Angeles), David B. Badesch(University of Colorado Anschutz Medical Campus), Nazzareno Galiè(Azienda USL di Bologna), Marion Delcroix(American Institute of Biological Sciences), Seán Gaine, Thomas R. Fleming(University of Washington), Olivier Sitbon(Inserm), Nick H. Kim(University of California San Diego), Andrew J. Peacock(Pulmonary Vascular Research Institute), Victor F. Tapson(Cedars-Sinai Medical Center)
Cited by 258
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
|European Heart Journal|2017|3k
ESC Guidelines for the management of grown-up congenital heart disease (new version 2010): The Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC)
|European Heart Journal|2010|2.3k
Clinical classification of pulmonary hypertension
|Journal of the American College of Cardiology|2004|1.9k